20:52 , Jul 31, 2018 |  BC Extra  |  Company News

Management tracks: Canbridge, Retrophin

Canbridge Life Sciences Ltd. (Beijing, China) hired May Orfali as CMO. She succeeds interim CMO Mark Goldberg. Orfali was executive director of global product development at Pfizer Inc. (NYSE:PFE). Rare disease company Retrophin Inc. (NASDAQ:RTRX) hired...
21:20 , May 11, 2018 |  BC Extra  |  Company News

Management tracks: Synlogic, Akari

Synlogic Inc. (NASDAQ:SYBX) said President and CEO Jose Carlos Gutiérrez-Ramos has resigned. CMO Aoife Brennan will serve as interim president and CEO while the synthetic biology company seeks a successor. Autoimmune and inflammatory disease company Akari...
00:38 , Jan 6, 2018 |  BioCentury  |  Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to a...
23:29 , Oct 6, 2017 |  BioCentury  |  Finance

High as a Kite

The acquisition of Kite Pharma Inc. by Gilead Sciences Inc. turned what would have been a flattish quarter into another period of outperformance, and relieved the cash constraints that could have prevented specialists from continuing...
19:55 , Sep 22, 2017 |  BC Week In Review  |  Financial News

Aldeyra raises $28.8M follow-on

Aldeyra Therapeutics Inc. (NASDAQ:ALDX), which focuses on diseases related to aldehydes, raised $28.8 million through the sale of 4 million shares at $7.25 in a follow-on underwritten by Cantor Fitzgerald and Laidlaw. The price is...
19:05 , Sep 19, 2017 |  BC Extra  |  Financial News

Aldeyra raises $25 million in follow-on

Aldeyra Therapeutics Inc. (NASDAQ:ALDX) raised $25 million through the sale of 3.5 million shares at $7.25 in a follow-on underwritten by Cantor Fitzgerald and Laidlaw. The price is a 20% discount to Aldeyra’s close of...
23:56 , Sep 14, 2017 |  BC Extra  |  Financial News

Aldeyra stock surge continues

Aldeyra Therapeutics Inc. (NASDAQ:ALDX) jumped $4.45 (70%) to $10.80 on Thursday as momentum continued following a Phase IIa data readout on Tuesday showing that ADX-102 ophthalmic solution significantly improved multiple signs and symptoms of dry...
23:34 , Sep 14, 2017 |  BC Week In Review  |  Clinical News

Aldeyra reports Phase IIa data for dry eye candidate

Aldeyra Therapeutics Inc. (NASDAQ:ALDX) reported data from a Phase IIa trial showing that ADX-102 ophthalmic solution significantly improved multiple signs and symptoms of dry eye disease compared to baseline. The trial enrolled 51 patients with...
20:11 , Sep 12, 2017 |  BC Extra  |  Clinical News

Aldeyra gains on Phase IIa data for dry eye candidate

Aldeyra Therapeutics Inc. (NASDAQ:ALDX) jumped $1.40 (33%) to $5.65 on Tuesday after reporting that ADX-102 ophthalmic solution significantly improved multiple signs and symptoms of dry eye disease in a Phase IIa trial. Next half, the...
20:30 , Jun 23, 2017 |  BC Week In Review  |  Clinical News

Aldeyra planning Phase III trial of ADX-102 despite Phase IIb miss in allergic conjunctivitis

Aldeyra Therapeutics Inc. (NASDAQ:ALDX) reported data from a Phase IIb trial in 154 patients with acute allergic conjunctivitis, including seasonal and perennial allergies, showing that 0.1% and 0.5% doses of ADX-102 ophthalmic drops both missed...